CYP19A1 and breast carcinoma: Adjuvant endocrine therapy (AET) combining gonadotropin-releasing hormone analogues (GnRHa) with tamoxifen (TAM) or aromatase inhibitors (AI) improves survival in premenopausal women with breast cancer compared to TAM and is increasingly prescribed.